Replies to post #155219 on Biotech Values

[biomaven0]

Yes, bromodomain inhibition seems to be an interesting oncology target pathway.

But Resverlogix looks like they don't even have a lead compound yet, although they do seem to be the one company focused in this space. But really they are too small to be chasing all these disparate areas, even if they do all emerge from their primary technology.

Peter

[biocqr]

$RVX... Bromodomain Inhibitors - an exciting new target in cancer research?

Sally Church...
http://pharmastrategyblog.com/2013/03/bromodomain-inhibitors-an-exciting-new-target-in-cancer-research.html/?utm_source=twitterfeed&utm_medium=twitter&utm_campaign=Feed%3A+PharmaStrategyBlog+%28Pharma+Strategy+Blog%29